证券代码：688246 证券简称：嘉和美康 公告编号：2025-035 减持计划的主要内容 公司于 2025 年 5 月 9 日收到弘云久康出具的《关于弘云久康数据技术(北京) 有限公司减持计划的告知函》，因自身流动性需求，股东弘云久康计划自本公告 披露之日起15个交易日后的90天内根据市场情况通过集中竞价方式减持其持有 的公司股份合计不超过 1,375,855 股，即不超过公司总股本的 1%。 嘉和美康（北京）科技股份有限公司 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 截至本公告披露日，嘉和美康（北京）科技股份有限公司（以下简称"嘉和 美康"或"公司"）股东弘云久康数据技术（北京）有限公司（以下简称"弘云 久康"）持有公司股份 9,861,786 股，占公司股份总数的 7.17%。上述股份为嘉 和美康首次公开发行并上市前取得的股份，且已于 2022 年 12 月 14 日起上市流 通。 减持价格按市场价格确定，若公司在上述减持计划 ...

Investment Rating - The report maintains a "Buy" rating for several companies in the AI and computing sector, including 亿道信息 (Yidao Information), 科大讯飞 (iFlytek), 唯科科技 (Weike Technology), 泓淋电力 (Honglin Electric), 嘉和美康 (Jiahe Meikang), 寒武纪 (Cambricon), 鼎通科技 (Dingtong Technology), and 迈信林 (Maixinlin) [15][50]. Core Insights - The computing industry has shown a strong relative performance, with a 1-month return of 14.6% compared to the Shanghai Composite Index's 6.1% [2]. - The launch of DeepSeek-Prover-V2 marks a significant advancement in mathematical reasoning models, achieving state-of-the-art performance in neural theorem proving [4][21]. - The Qwen3 model from 阿里通义千问 (Ali Tongyi Qianwen) has been introduced, showcasing competitive results in various benchmarks and significantly increasing its pre-training dataset size [6][30]. Summary by Sections 1. Computing Dynamics - The rental prices for computing power remain stable, with specific configurations priced at 28.64 RMB/hour for Tencent Cloud and 31.58 RMB/hour for Alibaba Cloud for A100-40G setups [20]. - DeepSeek-Prover-V2 was released on April 30, achieving advanced performance levels in theorem proving, solving 6 out of 15 selected problems from the AIME competition [21][22]. 2. AI Application Dynamics - Gemini's average stay duration increased by 3.45%, indicating growing user engagement [26]. - The Qwen3 model supports two thinking modes, allowing for both deep reasoning and quick responses, enhancing user flexibility [28]. 3. AI Financing Trends - Persona Identities Inc. completed a $200 million Series D funding round, reaching a valuation of $2 billion, highlighting the growing demand for AI-driven identity verification solutions [34][36]. 4. Market Review - The AI computing index and AI application index showed fluctuations, with notable gains in specific companies like 天源迪科 (Tianyu Dike) and 鸿博股份 (Hongbo Shares) [39][45]. 5. Investment Recommendations - The report suggests focusing on companies like 嘉和美康 (Jiahe Meikang) and 科大讯飞 (iFlytek) for potential growth, driven by advancements in AI and computing technologies [48][49].

Investment Rating - The investment rating for the computer industry is "Buy" [2] Core Insights - The computer industry is experiencing a bottoming out of demand in 2024, with significant differences in structural performance across various segments. Companies are enhancing operational efficiency to cope with the challenges [6][14] - The median revenue growth rate for the industry in 2024 is -1.59%, a decrease of 4.88 percentage points from 2023. The median net profit growth rate is -2.24%, down 8.35 percentage points from the previous year [15] - The report highlights that while revenue and profit metrics are declining, the rate of decline is slowing, indicating potential for improvement in Q1 2025 [15][16] Summary by Sections 1. 2024 Annual Report: Bottoming Demand and Efficiency Improvements - The report analyzes the performance of 208 listed companies in the computer industry, revealing that the overall revenue growth is stabilizing, and profit margins are showing signs of recovery [14][15] - Different segments within the industry show varying performance, with IT hardware, trusted computing, and smart vehicle sectors demonstrating positive growth trends [16][28] 2. Demand Stabilization and Financial Indicators - The report notes that contract liabilities are beginning to improve, and accounts receivable growth is declining, indicating a more stable financial environment [23][24] - Cash inflows from sales of goods and services have significantly increased, reflecting a positive trend in operational cash flow [24] 3. Investment Activity and Valuation Levels - The report indicates an increase in net cash outflow from investment activities, suggesting an expansion trend among companies [26] - As of April 30, 2025, the industry’s price-to-earnings (P/E) ratio is 46 times, with software companies showing a higher P/E increase compared to hardware companies [19][20] 4. Key Areas of Investment Value - The report identifies several key areas with strong investment potential, including AI applications, domestic software and hardware replacements, and the smart driving industry [20][21] - The acceleration of domestic orders in trusted computing and the expansion of the Harmony OS ecosystem are expected to enhance the competitive edge of leading companies in the industry [20][21]

Group 1 - The core viewpoint of the news is that 嘉和美康 (688246.SH) has reported its Q1 2025 financial results, highlighting significant institutional investor interest with 17 institutions holding a total of 55.132 million shares, representing 40.07% of the total share capital [1] - The top ten institutional investors collectively hold 38.12% of 嘉和美康's shares, with a slight decrease of 0.12 percentage points compared to the previous quarter [1] - The report indicates a dynamic shift in public fund holdings, with four public funds reducing their stakes, accounting for a decrease of 0.70%, while seven new public funds have disclosed holdings [2] Group 2 - Among social security funds, there was an increase in holdings from one fund, 易方达基金管理有限公司-社保基金17042组合, with an increase of 0.10% [2] - A total of 60 public funds were not disclosed in the current period, indicating a significant turnover in fund participation [2]

Financial Performance - The company's operating revenue for Q1 2024 was ¥122,559,648.25, representing a year-on-year increase of 14%[5] - The net profit attributable to shareholders was a loss of ¥11,850,583.19, with a net profit excluding non-recurring items at a loss of ¥13,035,632.66[5] - The company reported a net loss of RMB 109,927,096.29, worsening from a loss of RMB 98,076,513.10 in the previous period[15] - Net loss for Q1 2024 was CNY 16,002,665.06, an improvement from a net loss of CNY 31,354,681.56 in Q1 2023, representing a 48.9% reduction in losses[18] - The company reported a basic loss per share of CNY 0.09 for Q1 2024, improved from a loss of CNY 0.16 per share in Q1 2023[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥96,963,002.49[6] - Operating cash flow for Q1 2024 was negative CNY 96,963,002.49, an improvement from negative CNY 147,248,515.51 in Q1 2023[20] - Cash and cash equivalents decreased to RMB 534,817,691.78 from RMB 612,478,452.28, representing a decline of approximately 12.7%[13] - Cash and cash equivalents at the end of Q1 2024 were CNY 479,499,251.21, compared to CNY 461,002,187.62 at the end of Q1 2023, showing a year-over-year increase of 4.0%[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,690,827,310.92, an increase of 1.71% compared to the end of the previous year[6] - Current assets totaled RMB 2,165,674,578.41, down from RMB 2,210,465,358.33, indicating a decrease of about 2.0%[14] - Total liabilities rose to RMB 885,384,079.64 from RMB 817,330,281.60, marking an increase of approximately 8.3%[15] - Short-term borrowings increased significantly to RMB 259,720,809.73 from RMB 179,667,517.16, reflecting a rise of about 44.5%[15] - Total equity attributable to shareholders decreased to RMB 1,802,872,724.53 from RMB 1,821,580,993.57, a decline of about 1.0%[15] Research and Development - Research and development expenses totaled ¥59,773,809.35, accounting for 48.77% of operating revenue, a decrease of 1.23 percentage points year-on-year[6] - Research and development expenses decreased to CNY 32,077,752.04 from CNY 44,689,485.21, a decline of 28.4% year-over-year[16] Shareholder Information - The company had a total of 5,613 common shareholders at the end of the reporting period[11] - The largest shareholder, Xia Jun, holds 24,750,839 shares, representing 17.86% of the total shares[11] - The company has not reported any significant changes in shareholder participation in margin financing or securities lending activities during the reporting period[13] Government Support and Subsidies - The company received government subsidies amounting to ¥1,803,182.66, which are closely related to its normal business operations[7] - The company received CNY 9,060,482.97 in tax refunds during Q1 2024, significantly higher than CNY 2,468,938.31 in Q1 2023[20] Cost Management - The company reported a decrease in management expenses by 9.32% year-on-year, contributing to cost reduction and efficiency improvement[9] - Total operating costs decreased to CNY 143,969,298.04 from CNY 147,310,606.74, a reduction of 2.3% year-over-year[16] Investment Activities - The company incurred a total investment cash outflow of CNY 55,200,985.54 in Q1 2024, compared to CNY 5,694,232.70 in Q1 2023, reflecting increased investment activities[21] - Total cash inflow from financing activities was CNY 106,381,513.11 in Q1 2024, compared to CNY 18,000,000.00 in Q1 2023, indicating a substantial increase in financing[21]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2023, representing a year-on-year increase of 15%[12]. - The net profit attributable to shareholders was RMB 20 million, up 10% compared to the same period last year[12]. - The company's operating revenue for the first half of the year reached ¥291,957,202.04, representing a 15.89% increase compared to ¥251,918,066.48 in the same period last year[18]. - The net profit attributable to shareholders was -¥23,161,980.16, an improvement from -¥25,814,136.97 year-on-year[18]. - The company achieved a revenue of 291.96 million yuan in the reporting period, representing a year-on-year growth of 15.89%[71]. - The net profit attributable to shareholders was a loss of 23.16 million yuan, with the loss narrowing compared to the same period last year[71]. - The company reported a total revenue of 86,590,000 with a net profit of 11,008,957, indicating a strong financial performance[60]. - The company reported a net loss of ¥150,652,783.18, worsening from a loss of ¥127,490,803.02 in the previous period[156]. User Engagement and Market Expansion - User data showed an increase in active users by 25%, reaching a total of 500,000 users by the end of June 2023[12]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% growth in that region by the end of 2024[12]. - The company reported a user data increase of 20% in the last quarter, reflecting strong engagement with its digital health solutions[54]. - User data showed a growth of 25% in active users, totaling 2 million by the end of Q2 2023[118]. - Market expansion efforts have led to a 40% increase in market share in the Asia-Pacific region[117]. - The company plans to expand its market presence internationally, leveraging advanced technologies in its product offerings[54]. Research and Development - Research and development expenses increased by 20%, totaling RMB 5 million, focusing on enhancing existing technologies[12]. - The total R&D investment for the reporting period was CNY 122,111,851.30, representing an 18.31% increase year-on-year[48]. - The company applied for 26 new invention patents and obtained 4 invention patent authorizations during the reporting period, along with 52 software copyright registrations[45]. - The company is investing $50 million in R&D for new technologies aimed at enhancing user experience and operational efficiency[118]. - The company is focused on accelerating product layout and project progress, leading to increased R&D investment[49]. - The company is investing heavily in R&D, with a budget increase of 30% to enhance product innovation and technology development[120]. Product Development and Innovation - New product launches are expected to contribute an additional RMB 15 million in revenue for the second half of 2023[12]. - The core products of the smart medical product system include Clinical Decision Support System (CDSS), AI medical record quality control system, and intelligent triage system[26]. - The company is developing an intelligent single disease reporting system with a budget of $8 million, aiming to improve data accuracy and reduce manual reporting workload[54]. - The electronic medical record platform software sales revenue was 101.62 million yuan, showing a robust year-on-year growth of 27.55%[74]. - The newly launched hospital digital operation management platform aims to enhance operational efficiency and resource management in public hospitals[76]. Financial Guidance and Projections - The company has set a performance guidance of RMB 220 million in revenue for the full year 2023, indicating a growth target of 18%[12]. - The company expects a revenue guidance of $1.2 billion for the full year 2023, representing a 20% increase compared to 2022[117]. - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 20%[120]. Corporate Governance and Compliance - The board of directors confirmed that all financial reports are accurate and complete, with no significant omissions[12]. - No non-operational fund occupation by controlling shareholders was reported, ensuring financial integrity[12]. - The company has not reported any major litigation or arbitration matters during the reporting period[123]. - The company has not disclosed any plans for profit distribution or capital reserve transfer for the half-year period[105]. Market Position and Competitive Landscape - The company has maintained the number one position in the electronic medical record (EMR) market in China for nine consecutive years from 2014 to 2022, according to IDC data[37]. - The company's market share in the electronic medical record segment was 17.7% in 2022, ranking first ahead of competitors such as Weining Health (14.1%) and Haitai Medical (13.1%)[81]. - The company is experiencing intense competition in the medical informationization market, with many new entrants increasing market pressure[81]. Financial Health and Risks - The company's total assets decreased by 3.97% to ¥2,427,390,682.83 from ¥2,527,653,625.57 at the end of the previous year[18]. - The company faces risks related to core technology leakage and the potential loss of key technical personnel, which could adversely affect operations[80]. - The company’s business is subject to seasonal fluctuations, with significant revenue recognition typically occurring in the second half of the year[83]. - The overall financial health of the company is under scrutiny due to the declining comprehensive income and retained earnings[181]. Environmental and Social Responsibility - The management emphasized a commitment to sustainability, aiming for a 50% reduction in carbon emissions by 2025[116]. - The company has established an environmental management system and obtained ISO14001:2015 certification[110]. - The company has implemented green office measures to reduce carbon emissions[111].

Financial Performance - The company's operating revenue for Q1 2023 was ¥107,504,828.76, representing a year-on-year increase of 9.67%[5]. - Total operating revenue for Q1 2023 was ¥107,504,828.76, an increase of 9.98% compared to ¥98,027,811.38 in Q1 2022[18]. - Total operating costs decreased to ¥147,310,606.74 in Q1 2023 from ¥150,663,048.75 in Q1 2022, a reduction of 2.35%[18]. - Net profit for Q1 2023 was -¥31,354,681.56, an improvement from -¥37,033,436.97 in Q1 2022, reflecting a decrease in net loss of approximately 15.5%[19]. - Total profit for Q1 2023 was -¥40,234,419.96, compared to -¥45,243,906.72 in Q1 2022, indicating a reduction in losses[19]. Cash Flow - The net cash flow from operating activities was -¥147,248,515.51, indicating significant cash outflow[6]. - Operating cash flow for Q1 2023 was -¥147,248,515.51, slightly better than -¥157,222,315.08 in Q1 2022[20]. - The net cash flow from investing activities for Q1 2023 was -¥5,606,283.95, compared to -¥51,911,438.05 in Q1 2022, showing a significant reduction in cash outflow[21]. - The company generated ¥99,076,074.81 in cash from sales in Q1 2023, down from ¥105,143,461.21 in Q1 2022[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,406,706,803.49, down 4.78% from the end of the previous year[6]. - As of March 31, 2023, the total current assets amounted to RMB 2,114,696,359.84, a decrease of 6.45% from RMB 2,260,656,635.23 on December 31, 2022[14]. - The cash and cash equivalents decreased to RMB 618,345,584.94 from RMB 851,754,652.56, representing a decline of 27.36%[14]. - The total liabilities decreased to RMB 593,655,097.97, down 13.66% from RMB 687,479,956.03[16]. - The total equity attributable to shareholders decreased to RMB 1,788,687,399.99 from RMB 1,807,350,479.33, a decline of 1.83%[16]. - The company’s total assets decreased to RMB 2,406,706,803.49 from RMB 2,527,653,625.57, a reduction of 4.78%[15]. Shareholder Information - The company had a total of 5,549 common shareholders at the end of the reporting period[10]. - The largest shareholder, Xia Jun, held 17.91% of the shares, totaling 24,690,198 shares[10]. Research and Development - Research and development expenses totaled ¥53,749,878.60, accounting for 50.00% of operating revenue, a decrease of 3.08 percentage points[6]. - Research and development expenses for Q1 2023 were ¥44,689,485.21, a decrease of 6.9% from ¥48,010,998.55 in Q1 2022[18]. Earnings Per Share - The net profit attributable to shareholders was a loss of ¥22,660,220.88, with a diluted earnings per share of -¥0.16[5][6]. - The company reported a basic and diluted earnings per share of -¥0.16 for Q1 2023, an improvement from -¥0.20 in Q1 2022[19]. Audit Information - The company did not conduct an audit for the first quarter financial statements[4]. Inventory and Receivables - The inventory increased to RMB 557,170,481.95 from RMB 529,008,844.29, reflecting a growth of 5.32%[15]. - The accounts receivable slightly increased to RMB 412,786,738.47 from RMB 407,388,910.73, a rise of 1.00%[14]. Non-Recurring Gains - The company reported non-recurring gains of ¥1,777,752.68 after tax adjustments[8]. Borrowings - The company’s short-term borrowings significantly decreased to RMB 10,199,999.98 from RMB 85,094,154.82, a drop of 88.00%[16]. Return on Equity - The weighted average return on equity was -1.29%[6].

Financial Performance - The company reported a net loss of RMB 26,941,913.58 as of December 31, 2022, indicating that it does not meet the conditions for profit distribution[5]. - The company has not declared any statutory surplus reserves or discretionary reserves for the year 2022 due to negative retained earnings[5]. - The company's operating revenue for 2022 was approximately ¥716.95 million, representing a year-on-year increase of 9.97% compared to ¥651.94 million in 2021[22]. - Net profit attributable to shareholders for 2022 was approximately ¥64.58 million, a significant increase of 30.18% from ¥49.61 million in 2021[22]. - The basic earnings per share for 2022 was ¥0.47, a decrease of 2.08% from ¥0.48 in 2021[24]. - The weighted average return on equity decreased to 3.65% in 2022, down by 6.92 percentage points from 10.57% in 2021[24]. - The net cash flow from operating activities decreased by ¥61.73 million compared to the previous year, primarily due to delayed customer payments and increased upfront investments in medical information projects[25]. - The company's total net assets attributable to shareholders increased to approximately ¥1.81 billion by the end of 2022, a growth of 4.18% from ¥1.73 billion at the end of 2021[22]. - The company reported a net loss of approximately ¥28.29 million in the first quarter of 2022, followed by a profit of ¥63.10 million in the fourth quarter[28]. - The company reported a negative net cash flow from operating activities of -25,921.78 million, indicating significant cash flow challenges[120]. - The company has experienced significant seasonal revenue fluctuations, with most income recognized in the second half of the year, particularly in Q4[118]. Research and Development - Research and development expenses accounted for 24.71% of operating revenue in 2022, an increase of 5.47 percentage points from 19.24% in 2021[24]. - The company's R&D investment reached 177.15 million yuan, an increase of 41.24% compared to the previous year[36]. - Total R&D investment increased by 41.24% year-on-year, reaching ¥177,152,231.62, with R&D expenses accounting for 24.71% of operating revenue, an increase of 5.47 percentage points[90]. - The company has applied for 18 new invention patents and received authorization for 8 invention patents during the reporting period[37]. - The company has developed 5 new core technologies that significantly enhance medical data interconnectivity and utilization during the reporting period[82]. - The company has established a comprehensive marketing network across 15 provinces and municipalities, enhancing customer service and interaction[112]. Market Position and Strategy - The company is listed on the Shanghai Stock Exchange under the stock code 688246[19]. - The company has maintained the number one position in the electronic medical record (EMR) market in China for eight consecutive years from 2014 to 2021, according to IDC data[73]. - The company has over 1,550 hospital clients, including more than 500 top-tier hospitals, accounting for over 25% of all top-tier hospitals in China[73]. - The company aims to become a leading enterprise in the domestic medical information industry, focusing on clinical information construction and following the development path of "informationization-digitalization-intelligentization"[167]. - The company plans to enhance its competitive barriers in clinical medical data production, centralization, and application by leveraging its electronic medical record technology and innovative data generation models[169]. - The company is actively expanding its product line, including specialized electronic medical record systems and smart medical solutions, to address the needs of various types of medical institutions[170]. Governance and Compliance - The company has received a standard unqualified audit report from Da Hua Certified Public Accountants[4]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for providing guarantees[7]. - The company has not made any significant governance arrangements or special matters applicable[8]. - The company has implemented multiple quality management systems, including ISO9001 and ISO13485, ensuring high standards in data and business security[112]. - The company confirmed the remuneration assessment system for directors and senior management, which requires approval from the board and shareholders[197]. Risks and Challenges - The company has detailed potential risks in its report, which investors should be aware of[6]. - The company faces risks related to increasing accounts receivable, which may impact cash flow and operational performance[120]. - The company is at risk of losing core technical personnel, which could adversely affect its operations and technological development[115]. - The company has identified risks associated with project implementation without signed contracts, leading to potential revenue recognition issues[116]. - The company faces risks related to changes in tax incentives, which could increase tax liabilities if the conditions for tax benefits are not met[123]. Investment and Financial Management - The company has completed the investment of $5,772,470 in the Emergency Clinical Information System V2.0, with a total expected investment of $21,250,000[94]. - The company has invested $4,626,911 in the Jiahe Platform Data Center V6.0, with a total expected investment of $14,000,000, achieving significant improvements in data quality and processing efficiency[94]. - The company has completed the investment of $3,895,769 in the Haisen Clinical Decision Support System V3.0, with a total expected investment of $7,100,000, enhancing clinical decision-making through natural language processing[94]. - The company has invested $2,773,991 in the Haisen AI Teaching Assistant System V1.0, with a total expected investment of $4,450,000, aimed at improving clinical skills for specific rare diseases[95]. - The company has completed the investment of $6,913,104 in the Haisen Big Data Research and Analysis Platform V3.0, with a total expected investment of $12,000,000, facilitating retrospective clinical research[95]. Product Development and Innovation - The company plans to continue expanding its product offerings and enhancing its technological capabilities in response to market trends and policy support[24]. - The company is committed to continuous technological innovation, exploring applications of cloud computing, IoT, big data, AI, and mobile internet in the medical information field[168]. - The company is focused on improving the user experience and market competitiveness of its product lines through upgrades and iterations of existing systems[170]. - The company is leveraging AI applications to promote the capabilities and service levels of grassroots medical institutions, supporting the implementation of hierarchical medical care policies[170]. Customer Engagement and Market Expansion - The company is enhancing its brand awareness and overall strength through competitive compensation systems and equity incentives to attract high-quality talent[172]. - The company is focused on expanding its market presence and developing new technologies in the healthcare sector[194]. - The company is involved in multiple partnerships and collaborations to enhance its service offerings in the healthcare industry[194]. - The company plans to implement new strategies to enhance customer engagement, targeting a J% increase in customer retention rates[185].

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2024, representing a year-on-year increase of 15%[14]. - The company's operating revenue for the first half of the year was approximately CNY 300.48 million, representing a 2.92% increase compared to the same period last year[19]. - The total revenue for the reporting period was 604.5 million RMB, with a net profit of 122.36 million RMB, indicating a strong financial performance[52]. - The company achieved a revenue of 300.48 million yuan, representing a year-on-year growth of 2.92%[62]. - The company reported a significant performance decline, with a reduction in revenue by 20% year-over-year[115]. - The company reported a net loss of CNY 125,548,761.89 for the current period, compared to a net loss of CNY 84,417,293.52 in the previous period, indicating a worsening financial performance[186]. User Engagement and Market Expansion - User data indicates that the active user base has grown to 1.5 million, up 20% compared to the same period last year[14]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[14]. - The company is expanding its market presence in Asia, targeting a 30% increase in market share by the end of 2025[116]. - User data showed a growth of 30% in active users year-over-year, reaching 1.5 million users[118]. Research and Development - Research and development expenses increased by 30% to RMB 15 million, focusing on innovative healthcare solutions and technology advancements[14]. - The company has a strong focus on R&D, integrating traditional software technology with new-generation information technology to enhance its product offerings[33]. - The company applied for 26 new invention patents and obtained 6 invention patent authorizations during the reporting period, bringing the total number of authorized invention patents to 51[39]. - The company has developed six core technologies for specialized electronic medical records, enhancing data usability and precision in medical decision-making[56]. - The company has made significant investments in R&D for smart clinical, smart management, and medical AI technologies[63]. Technology and Product Development - The company has launched a new electronic medical record system, which is anticipated to increase operational efficiency by 25%[14]. - The company has developed a new core technology, "Large Model Assisted Electronic Medical Record Automatic Generation Technology," which utilizes deep learning to generate structured medical documents, reducing manual input time for doctors[33]. - The company has developed an intelligent, automated, and comprehensive quality control platform for medical records, which aims to enhance the quality control process in hospitals and is currently in the trial operation phase[51]. - The company has completed the development of a smart hospital system, which includes a patient-side app and a doctor-side workstation app, aimed at enhancing communication and service efficiency[52]. - The company is collaborating with its subsidiary to upgrade emergency diagnosis systems, integrating imaging and ultrasound diagnostic products[66]. Financial Management and Risks - The company has recognized a tax reduction to 15% for its subsidiaries recognized as high-tech enterprises, but future changes in tax policies could adversely affect its financial performance[80]. - The company faces risks related to the medical information industry, including potential policy changes that could impact order acquisition and revenue growth stability[81]. - The company has improved its internal control management and cash flow management to strengthen its risk resistance capabilities[62]. - The company reported a negative net cash flow from operating activities of -189.85 million yuan, primarily due to delayed payments from clients and high upfront project investments[78]. Shareholder and Equity Information - The company did not propose any profit distribution or capital reserve fund transfer plans for the half-year period[100]. - The company has committed to a cash dividend policy, ensuring reasonable returns to investors, with specific arrangements for profit distribution outlined in the company's articles of association[121]. - The total number of ordinary shareholders as of the reporting period end was 5,867[146]. - The company’s total share capital was adjusted to 137,570,846 shares after the exercise of stock options and the cancellation of repurchased shares[145]. Environmental and Social Responsibility - The company has implemented green office measures to reduce carbon emissions[108]. - The company is not classified as a key pollutant unit and does not belong to heavily polluting industries[106]. - The company has established an environmental management system and obtained ISO14001:2015 certification[107]. - There were no administrative penalties related to environmental issues during the reporting period[106].

Financial Performance - The company's operating revenue for the third quarter was ¥175,272,087.55, a decrease of 28.68% compared to the same period last year[4]. - The net profit attributable to shareholders was -¥13,787,288.80, representing a decline of 133.47% year-over-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥13,248,115.02, down 132.78% from the previous year[4]. - The net profit attributable to shareholders for the year-to-date period was -¥41,259,537.59, a significant decrease of 328.81% compared to the same period last year[4]. - The company reported a net loss of CNY 72,563,428.01 for the first three quarters of 2024, compared to a loss of CNY 19,149,698.80 in the same period of 2023[21]. - The total profit (loss) for the period was -73,586,781.02 RMB, compared to -19,188,968.02 RMB in the previous period[22]. - The net profit attributable to the parent company's shareholders was -41,259,537.59 RMB, down from 18,032,060.98 RMB year-over-year[23]. - The basic and diluted earnings per share for the third quarter were both -¥0.10, reflecting a decline of 133.33% year-over-year[5]. - The basic and diluted earnings per share were both -0.30 RMB, compared to 0.13 RMB in the same period last year[23]. Research and Development - Research and development expenses totaled ¥56,676,943.62, accounting for 32.34% of operating revenue, an increase of 9.06 percentage points year-over-year[5]. - Research and development expenses for the first three quarters of 2024 amounted to CNY 116,607,510.81, compared to CNY 127,290,711.34 in 2023, indicating a decrease of 8.3%[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,659,989,627.58, a slight increase of 0.54% from the end of the previous year[5]. - Total assets as of September 30, 2024, were CNY 2,659,989,627.58, slightly up from CNY 2,645,633,863.79 at the end of 2023[17]. - Total liabilities increased to CNY 889,967,888.54 as of September 30, 2024, compared to CNY 817,330,281.60 at the end of 2023, marking an increase of 8.8%[17]. - The company's equity attributable to shareholders decreased to CNY 1,773,506,823.62 as of September 30, 2024, down from CNY 1,821,580,993.57 at the end of 2023, a decline of 2.6%[17]. Cash Flow - The company reported a cash flow from operating activities of -¥162,335,536.26 for the year-to-date period[4]. - Cash flow from operating activities generated a net outflow of -162,335,536.26 RMB, an improvement from -226,519,885.58 RMB in the previous year[24]. - Cash inflow from investment activities was 30,477,529.64 RMB, significantly lower than 110,636,068.16 RMB in the prior year[25]. - Cash flow from financing activities resulted in a net inflow of 65,093,607.61 RMB, compared to a net outflow of -54,693,186.32 RMB last year[25]. - The total cash and cash equivalents at the end of the period were 303,496,223.85 RMB, down from 382,650,059.49 RMB at the end of the previous year[25]. - Cash and cash equivalents decreased to CNY 328,568,394.05 as of September 30, 2024, down from CNY 612,478,452.28 at the end of 2023, representing a decline of 46.3%[16]. - The company received 12,878,824.78 RMB in tax refunds, an increase from 8,746,067.31 RMB in the previous year[24]. - The company reported a decrease in cash received from sales of goods and services, totaling 366,295,717.03 RMB, compared to 371,112,264.71 RMB in the same period last year[24]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,576[11]. - The largest shareholder, Xia Jun, holds 24,750,839 shares, representing 17.99% of total shares[11]. - The second largest shareholder, Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, holds 16,812,069 shares, representing 12.22%[11]. - The third largest shareholder, Hongyun Jiukang Data Technology (Beijing) Co., Ltd., holds 11,650,207 shares, representing 8.47%[11]. - The top 10 shareholders collectively hold significant stakes, with the largest three shareholders accounting for 38.68% of total shares[11]. - The company has a total of 4,604,868 shares held by Suzhou Saifu Puxin Medical Health Industry Investment Center, representing 3.35%[12]. - The total number of shares held by the top 10 unrestricted shareholders is 42,000,000 shares[12]. - The company has engaged in margin trading, with specific shares held through this method, including 1,765,000 shares by Beijing Haoqing Wealth Investment Management Co., Ltd.[13]. - The company has not reported any significant changes in shareholder structure due to margin trading activities[14]. Operational Status - There are no other important reminders regarding the company's operational status during the reporting period[14]. - The company did not execute any mergers or acquisitions during the reporting period[26].